Noncoding SNP at rs1663689 represses ADGRG6 via interchromosomal interaction and reduces lung cancer progression

Xinyue Lei,Xiaoling Tian,Hao Wang,Xinran Xu,Guoli Li,Wenxu Liu,Dan Wang,Zengtuan Xiao,Mengzhe Zhang,Mulin Jun Li,Zhenfa Zhang,Zhenyi Ma,Zhe Liu

DOI: https://doi.org/10.15252/embr.202256212

IF: 9.071

2023-05-10

EMBO Reports

Abstract:This study shows a trans‐effect of a noncoding genetic variant and suggests a personalized treatment strategy for lung cancer patients harboring the T/T genotype at rs1663689. A previous genome‐wide association study (GWAS) revealed an association of the noncoding SNP rs1663689 with susceptibility to lung cancer in the Chinese population. However, the underlying mechanism is unknown. In this study, using allele‐specific 4C‐seq in heterozygous lung cancer cells combined with epigenetic information from CRISPR/Cas9‐edited cell lines, we show that the rs1663689 C/C variant represses the expression of ADGRG6, a gene located on a separate chromosome, through an interchromosomal interaction of the rs1663689 bearing region with the ADGRG6 promoter. This reduces downstream cAMP‐PKA signaling and subsequently tumor growth both in vitro and in xenograft models. Using patient‐derived organoids, we show that rs1663689 T/T—but not C/C—bearing lung tumors are sensitive to the PKA inhibitor H89, potentially informing therapeutic strategies. Our study identifies a genetic variant‐mediated interchromosomal interaction underlying ADGRG6 regulation and suggests that targeting the cAMP‐PKA signaling pathway may be beneficial in lung cancer patients bearing the homozygous risk genotype at rs1663689.

cell biology,biochemistry & molecular biology